Plasma Fibrinolysis Inhibitor Levels in Acute Stroke Patients with Thrombolysis Failure.
- Author:
Seo Hyun KIM
1
;
Sang Won HAN
;
Eun Hee KIM
;
Dong Joon KIM
;
Kyung Yul LEE
;
Dong Ik KIM
;
Ji Hoe HEO
Author Information
- Publication Type:Original Article
- Keywords: Fibrinolytic agents; Acute stroke; Plasminogen activator inhibitor type 1; Thrombin-activatable fibrinolysis inhibitor
- MeSH: Angiography; Arteries; Carboxypeptidase U; Enzyme-Linked Immunosorbent Assay; Fibrinolysis*; Fibrinolytic Agents; Healthy Volunteers; Humans; Myocardial Infarction; Plasma*; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Stroke*
- From:Journal of Clinical Neurology 2005;1(2):142-147
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND PURPOSE: Thrombolytics-induced recanalization fails in a significant portion of patients with ischemic stroke, which is partly due to the resistance of clots to lysis by thrombolytic agents. The pretreatment level of endogenous fibrinolysis inhibitors may affect such thrombolysis failure. METHODS: We studied 43 stroke patients whose arterial recanalization had been evaluated by angiography, and whose blood had been obtained prior to the administration of thrombolytic agents. Plasma samples from 34 healthy volunteers were used as normal controls. Plasminogen activator inhibitor type 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels were quantified using an enzyme-linked immunosorbent assay. RESULTS: Arteries were recanalized [Thrombolysis in Myocardial Infarction (TIMI) grade 2 or 3] in 30 patients, but not (TIMI grade 0 or 1) in the other 13. The plasma PAI-1 level was significantly higher in patients without recanalization (nonrecanalization) than in those with recanalization and in normal controls. The TAFI levels did not differ among the groups. CONCLUSIONS: The pretreatment PAI-1 levels are increased in acute stroke patients with thrombolysis failure.
